Damon Joe · 28 Jul 2022

The report features an extensive study on the extensive study of the current landscape and the likel..

Damon Joe · 27 Jul 2022

The report features an extensive study on the extensive study of the current landscape and the likel..

Damon Joe · 26 Jul 2022

The development of such biologics is inherently complex, and many drug developers are now seeking to..

Damon Joe · 25 Jul 2022

Since the approval of the first antisense drug in 1998, oligonucleotides have paved their way into t..

Damon Joe · 21 Jul 2022

Most of the deals reported in the public domain are licensing and commercialization agreements..

Damon Joe · 21 Jul 2022

More than 78% of the therapies are being evaluated in early stages, either as monotherapies or in co..

Damon Joe · 20 Jul 2022

The report features an extensive study of the current market landscape of companies offering manufac..

Damon Joe · 20 Jul 2022

A detailed discussion on the need for regulatory review / oversight across different stages of the m..

Damon Joe · 19 Jul 2022

Most of the deals reported in the public domain are licensing and commercialization agreements..

Damon Joe · 19 Jul 2022

More than 78% of the therapies are being evaluated in early stages, either as monotherapies or in co..